| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the MRC Centre for Immune Regulation at University of Birmingham Liver Research Labóratories, Queen Elizabeth Hospital, Birmingham, United Kingdom
This study demonstrates a novel role for the Fas pathway in the promotion of local tumor growth by inducing apoptotic cell death in normal hepatocytes at the tumor margin in colorectal hepatic metastases. Our results show that >85% of lymphocytes infiltrating colorectal liver cancer express high levels of Fas-ligand (Fas-L) by flow cytometry. Using immunohistochemistry of tumor tissue we showed strong Fas expression in noninvolved hepatocytes, whereas Fas-L expression was restricted to tumor cells and infiltrating lymphocytes at the tumor margin. Apoptosis was observed in 45 ± 13% of the Fashigh hepatocytes at the tumor margin whereas only 7 ± 3% tumor cells were apoptotic (n = 10). In vitro, primary human hepatocytes expressed Fas receptor and crosslinking with anti-Fas antibody induced apoptosis in 44 ± 5% of the cells compared with 4.6 ± 1.0% in untreated controls (P = 0.004). Both tumor-infiltrating lymphocytes (TIL) and human metastatic colon cancer cells cells are able to induce Fas-mediated apoptosis of primary human hepatocytes in coculture cytotoxic assays. TIL induced apoptosis in 47 ± 9% hepatocytes compared with control 4.3 ± 1.0% (P = 0.009) and this effect was reduced by anti-human Fas-L mAb (18.7 ± 1.3%, P = 0.009). SW620 cells induced apoptosis in 26 ± 2% hepatocytes compared with control 5.6 ± 1.7% (P = 0.004) and this was reduced to 11.2 ± 1.8% (P = 0.004) in the presence of anti-human Fas-L mAb. These data suggest that the inflammatory response at the margin of colorectal liver metastases induces Fas expression in surrounding hepatocytes, allowing them to be killed by Fas-L-bearing TIL or tumor cells and facilitating the invasion of the tumor into surrounding liver tissue.
This article has been cited by other articles:
![]() |
M. S. Renna, S. G. Correa, C. Porporatto, C. M. Figueredo, M. P. Aoki, M. G. Paraje, and C. E. Sotomayor Hepatocellular apoptosis during Candida albicans colonization: involvement of TNF-{alpha} and infiltrating Fas-L positive lymphocytes Int. Immunol., December 1, 2006; 18(12): 1719 - 1728. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Parker and C. A. Picut Liver Immunobiology Toxicol Pathol, January 1, 2005; 33(1): 52 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-i. Kusakai, A. Suzuki, T. Ogura, S.'i. Miyamoto, A. Ochiai, M. Kaminishi, and H. Esumi ARK5 Expression in Colorectal Cancer and Its Implications for Tumor Progression Am. J. Pathol., March 1, 2004; 164(3): 987 - 995. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-G. Yoo, S. H. Oh, E. S. Park, H. Cho, N. Lee, H. Park, D. K. Kim, D.-Y. Yu, J. K. Seong, and M.-O. Lee Hepatitis B Virus X Protein Enhances Transcriptional Activity of Hypoxia-inducible Factor-1{alpha} through Activation of Mitogen-activated Protein Kinase Pathway J. Biol. Chem., October 3, 2003; 278(40): 39076 - 39084. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-J. Liu, A. Nilsson, S. Oredsson, V. Badmaev, W.-Z. Zhao, and R.-D. Duan Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells Carcinogenesis, December 1, 2002; 23(12): 2087 - 2093. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Whartenby, E. E. Straley, H. Kim, F. Racke, V. Tanavde, K. S. Gorski, L. Cheng, D. M. Pardoll, and C. I. Civin Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation Blood, October 16, 2002; 100(9): 3147 - 3154. [Abstract] [Full Text] [PDF] |
||||
![]() |
H H J Backus, C J Van Groeningen, W Vos, D F Dukers, E Bloemena, D Wouters, H M Pinedo, and G J Peters Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases J. Clin. Pathol., March 1, 2002; 55(3): 206 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
I TINHOFER, H WYKYPIEL, I MARSCHITZ, T HENN, R GREIL;, M W BENNETT, J O'CONNELL, D ROCHE, C BRADY, J KELLY, et al. Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway • Reply Gut, May 1, 2000; 46(5): 738 - 740. [Full Text] [PDF] |
||||
![]() |
M. J. Pinkoski, T. Brunner, D. R. Green, and T. Lin Fas and Fas ligand in gut and liver Am J Physiol Gastrointest Liver Physiol, March 1, 2000; 278(3): G354 - G366. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |